Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents

Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents

The cytidine analogues azacytidine and 5-aza-2'-deoxycytidine (decitabine) are commonly used to treat myelodysplastic syndromes, with or without a myeloproliferative component. It remains unclear whether the response to these hypomethylating agents results from a cytotoxic or an epigenetic effe...

Full description

Bibliographic Details
Main Authors: Merlevede, Jane, Droin, Nathalie, Qin, Tingting, Meldi, Kristen, Yoshida, Kenichi, Morabito, Margot, Chautard, Emilie, Auboeuf, Didier, Fenaux, Pierre, Braun, Thorsten, Itzykson, Raphael, de Botton, Stéphane, Quesnel, Bruno, Commes, Thérèse, Jourdan, Eric, Vainchenker, William, Bernard, Olivier, Pata-Merci, Noemie, Solier, Stéphanie, Gayevskiy, Velimir, Dinger, Marcel E., Cowley, Mark J., Selimoglu-Buet, Dorothée, Meyer, Vincent, Artiguenave, François, Deleuze, Jean-François, Preudhomme, Claude, Stratton, Michael R., Alexandrov, Ludmil B., Padron, Eric, Ogawa, Seishi, Koscielny, Serge, Figueroa, Maria, Solary, Eric
Format: Online
Language:English
Published: Nature Publishing Group 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770084/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770084/

Similar Items